Pharming « Terug naar discussie overzicht

Valeant draadje

353 Posts, Pagina: « 1 2 3 4 5 6 ... 10 11 12 13 14 15 16 17 18 » | Laatste

Omlaag ↓

[verwijderd] 2 november 2016 13:57

Valeant: Salix Sale Could Mean Major Upside $VRX
www.seekingalpha.com/article/4018121

By Parke Shall
Yesterday, late in the day, it was reported that Valeant (NYSE:VRX) was closing in on the sale of Salix. The potential sale was reported to be as much as $10 billion, with $8.5 billion upfront in cash and the remainder coming in the form of revenue royalties. This represents almost a 30% discount to what Valeant paid for the company just a few years ago. It also marks the first major potential asset sale that the company would be making since it has been trying to delever itself. Reuters reported,
Valeant Pharmaceuticals International Inc is in talks to sell its Salix stomach-drug business to Japan's Takeda Pharmaceutical Co Ltd, according to people familiar with the matter.
The deal could raise as much as $10 billion for the indebted drugmaker, the people said, asking not to be identified because the discussions are private. There is no guarantee that the discussions will lead to a deal, they said.
Valeant is working with investment bank Morgan Stanley on the sale, the people said. Another bidder may also be interested in the Salix business, they added.
News of the talks was first reported by the Wall Street Journal.
We believe such a sale could cause the equity to appreciate meaningfully from here, even with the stock at $23. We want to explain why in this article.
This move for the company falls in line with the strategy but they pitched to the market on several occasions, both by the company and through board member William Ackman. For some time now, the narrative has been that the company will sell off its non-core assets and focus on its core cash generating properties. The company also stated that it had actually reconsidered renaming itself Bausch & Lomb, the Eyecare franchise that is at the epicenter of the company's core consumer business.

Speculation had been rampant over the last few months that the company was not going to be at be able to divest of its non-core assets in such a "fire sale". The fact that there is a meaningful bid for Salix out there and is an immense positive for the company. It also is the first positive news for Equity holders in a long time.
To put it simply, Valeant's equity has been priced at levels that are suggesting a complete and total collapse of the company and potential bankruptcy. The debt market had been pricing the company with significantly more confidence, but likely only because debt instruments in the capital structure are senior to equity, which is lowest in the capital structure. In order for the equity to survive, there needs to be a significant amount of relief when it comes to the company's potential bankruptcy scenarios.
For a while, we had been suggesting that asset sales and potentially a spin off of one or more of the company's divisions could be a good way to distribute the debt and balance things while at the same time allowing equity multiples to expand. This sale, if it consummates, would do just that. It could potentially hack away at the company's significant debt load, reducing it by around 30% in one shot. This would help stabilize the business and help the company's ability to service its debt on a regular basis. All the while, the company's main cash generator in Bausch & Lomb would stay intact.
From this, we expect there to be far more price expansion if the deal is formally announced. Judging by several articles that were out last night, it looks as though only the formalities need to be finished up. Takeda stock was halted over night.
Two things can happen after this divestiture takes place.
The first is that equity holders will see appreciation in their investment.
The second is that the equity then becomes available for the company to use as a potential weapon to tackle more debt. The company would never want to go out in issue equity at prices that are suggesting the company will go bankrupt. However, if the equity catches a legitimate bid and gets back perhaps above the $40 level, the company may want to consider issuing a modest amount of equity to pay off more of its long-term debt. This, in turn should have a net positive affect on the price of the equity despite the dilution.
Regardless, this divestiture would be a significant step forward in the "new" Valeant. As we wrote yesterday, we are long and plan on continuing to hold. We are also hedged slightly with puts.
Disclosure: I am/we are long VRX.

[verwijderd] 2 november 2016 15:26

Maar Lower kunnen gewoon vandaag weer 20% zakken er bestaat veel angst dat het niet gaat worden wat men hoopt.
En als altijd slechte raadgever.

Ruud..

[verwijderd] 2 november 2016 15:28

November 2, 2016, 9:54 A.M. ET
Valeant: Selling Salix a Warning of Trouble to Come?

By Ben Levisohn

Valeant Pharmaceuticals International (VRX) has confirmed that it is in talks to sell its Salix Pharmaceutical business. Wells Fargo’s David Maris and team liken it to “selling the stove to keep the restaurant.” They explain why:

This is the latest in a string of surprising news that we believe is all connected and is more of an acknowledgment of significant challenges rather than a resolution. Valeant has confirmed discussions regarding a potential Salix sale; this comes just one day after Bloomberg reported the Department of Justice may be preparing accounting fraud charges against Valeant and/or its former executives, and just 2 weeks after the company unexpectedly raised prices on a number of products, including the two largest revenue generators. Valeant may be trying to avoid a potential default, knowing accounting fraud charges, class action suits, and pending maturities may significantly outstrip its ability to meet its obligations. In other words, we think Valeant would not sell its core assets if things were going well.

Shares of Valeant Pharmaceuticals International have tumbled 6.5% to $22.30 at 9:50 a.m. today.

Ruud.. nu al weer 7.12% down

[verwijderd] 2 november 2016 15:56

www.bloomberg.com/gadfly/articles/201...

Het gaat er echt om spannen.

Ruud..

bik 2 november 2016 16:03

ALWEER>Dat roept U al 15 jaren,tijd dat [Verwachting]U komt bijvallen.Ondertussen zijn de meeste alle belegers hun centjes kwiet,mien jong.Grmpffft

[verwijderd] 2 november 2016 16:53

Valeant Stock: Why Traders Are Going Nuts Over VRX Stock

vrx stockWhat Does VRX Stock’s Rally Mean?

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) made an impressive recovery today as VRX stock rose 30% despite the ongoing investigation into two of the company’s former executives.

Yesterday, VRX stock looked all but dead after falling 12.02% as a result of a fraud investigation undertaken by U.S. prosecutors. This is coming on the heels of an already abysmal couple of years for Valeant as the stock has dropped to less than a tenth of its peak value of $335.32.

For today, at least, VRX stock has something to celebrate with its resurgence. While still nowhere near the powerhouse Wall-Street-darling company it once was, Valeant can at least count today’s climb as a victory.

This stock will be one to watch in the coming months. Sources told Bloomberg that charges could be levied within a couple of weeks. The results of this investigation and the trial of the executives will definitely draw investor scrutiny of VRX stock, for ill or good. (Source: “Valeant stock plunges on report of criminal probe of former top executives,” Financial Post, October 31, 2016.)

Several other investigations are also taking place into Valeant, and any news dropping in relation to the other cases could shake Valeant’s value even more.

Pharmaceutical companies have garnered a lot of negative headlines recently for the price hiking of medication, thanks to the antics of executives like Martin Shkreli and his company, Turing Pharmaceuticals LLC, which infamously raised the price of its antiparasitic drug “Daraprim” by over 5000%. (Source: “Lunch with the FT: Can Martin Shkreli defend corporate greed?,” Financial Times, October 27, 2016.)

Former presidential-hopeful Senator Bernie Sanders tweeted about one such company two weeks ago, complaining that Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) had spiked cancer medication medicine to an unaffordable level. The tweet is said to have cost the company a 15% fall in its stock. ARIA stock has only continued on a downward spiral, losing almost a third of its value since the tweet. (Source: “Bernie Sanders tweet sends shares of Ariad Pharmaceuticals down 15%,” CNBC, October 15, 2016.)

The fraud charges and allegations of price manipulation levied at VRX stock are certainly bad publicity, and as seen above, this can drastically impact these pharmaceutical companies. However, today’s jump provides evidence to the contrary. We’ll be keeping a close eye on VRX stock in the days to come. Could this be a blip in the radar or a sign of a resurrection for the embattled company?

[verwijderd] 2 november 2016 17:02

VRX -7.59%

[verwijderd] 3 november 2016 09:03

Valeant weighs sale of eye-surgery equipment divison
www.seekingalpha.com/news/3220269

• As it looks to offload its Salix stomach-drug business to pare debt, Valeant Pharmaceuticals (NYSE:VRX) is exploring a sale of its eye-surgery equipment unit for as much as $2.5B, WSJ reports.
• The drugmaker has also been sued on behalf of former investors in Sprout Pharmaceuticals, which it bought last year for $1B, over its alleged failure to market the "the female Viagra" pill Addyi successfully.

[verwijderd] 3 november 2016 09:22

3 62 176 0.213
5 127 199 0.212
5 193 655 0.211
26 752 016 0.210
4 27 950 0.209
5 87 500 0.208
4 66 500 0.207
59 1 403 865 TOTAL
Vente Qte. Ordres
0.215 57 658 2
0.216 48 800 3
0.217 9 151 1
0.218 10 000 1
0.219 45 672 2
0.220 52 000 4
0.221 69 244 5
TOTAL 457 064 29

www.boursorama.com/cours.phtml?symbol...

Objectif de cours 3 mois : 1.62 EUR

Ecart de : 660.56 %

Notes des analystes : 1

Acheter

5
Vendre
4
Alléger
3
Conserver
2
Renforcer
1
Acheter

[verwijderd] 3 november 2016 11:58

Objectif de cours 3 mois : 1.62 EUR

Ecart de : 664.15 %

Notes des analystes : 1

Acheter

5
Vendre
4
Alléger
3
Conserver
2
Renforcer
1
Acheter

[verwijderd] 3 november 2016 13:54

Zou die stukjes zijn weer binnen, op naar de volgende aanbieding :-)

[verwijderd] 3 november 2016 15:30

quote:
bik schreef op 2 november 2016 16:03:
ALWEER>Dat roept U al 15 jaren,tijd dat [Verwachting]U komt bijvallen.Ondertussen zijn de meeste alle belegers hun centjes kwiet,mien jong.Grmpffft

puzzeltje zijn dat A, Slimme B, Domme C,klungelende D, Rare kwasten.?

Ruud..

[verwijderd] 3 november 2016 19:50

Is Valeant Lighting Dollar Bills On Fire With Its Salix Sale? $VRX
www.seekingalpha.com/article/4018833

@chiddix
Some seem to forget that Valeant has received some material value over past two years owning Salix. EBITDA in 2015 and 2016, for illustrative purposes, may have been $600mm in 2015 and may be $900 mm in 2016. So subtracting 2015 and 2016 related free cash flows (after tax) from price for which Valeant acquired Salix would, in affect, reduce that purchase price (e.g., from $14.5b to $13.1b).

Diegy 4 november 2016 14:50

Kan iemand mij vertellen wat de meest recente koersdoelen zijn voor valeant? Kan het zo snel niet vinden.

Diegy 4 november 2016 15:54

Koers van valeant is in 2 maanden tijd van 31 dollar naar 19.50 dollar gegaan. Afgelopen dinsdag kwam het bericht,

Dat de divisie die medicijnen maakt tegen maagklachten verkopen aan het Japanse Takeda. De divisie zou 10 mrd op moeten leveren. Dat meldt Wall Street Journal op basis van anonieme bronnen.

Volgens de krant zijn gesprekken over de overname in een vergevorderd stadium. De deal is echter niet zeker, omdat er nog een andere potentiële koper in de race zou zijn. Welk bedrijf dit is, is niet duidelijk.

De koers steeg dinsdag naar 24 dollar op bovenstaand bericht. De gesprekken zijn in een vergevorderd stadium. Dus zal niet lang meer duren voordat de deal bekend word gemaakt. Moet je nagaan hoe hard de koers dan omhoog zal gaan. Als bij bericht over eventuele verkoop koers al stijgt naar 24 dollar.

[verwijderd] 4 november 2016 15:55

quote:
Diegy schreef op 4 november 2016 15:54:
Koers van valeant is in 2 maanden tijd van 31 dollar naar 19.50 dollar gegaan. Afgelopen dinsdag kwam het bericht,

Dat de divisie die medicijnen maakt tegen maagklachten verkopen aan het Japanse Takeda. De divisie zou 10 mrd op moeten leveren. Dat meldt Wall Street Journal op basis van anonieme bronnen.

Volgens de krant zijn gesprekken over de overname in een vergevorderd stadium. De deal is echter niet zeker, omdat er nog een andere potentiële koper in de race zou zijn. Welk bedrijf dit is, is niet duidelijk.

De koers steeg dinsdag naar 24 dollar op bovenstaand bericht. De gesprekken zijn in een vergevorderd stadium. Dus zal niet lang meer duren voordat de deal bekend word gemaakt. Moet je nagaan hoe hard de koers dan omhoog zal gaan. Als bij bericht over eventuele verkoop koers al stijgt naar 24 dollar.

Die maagklachtmedicijnen maken ze voor hun eigen aandeelhouders... kijk nou maar uit met Valeant...

Diegy 4 november 2016 16:07

Je maakt mij niet wijs dat de koers op een bericht dat ze in een vergevorderd stadium zijn met de gesprekken de koers stijgt naar 24 dollar en dat als van de week de deal definitief bekend word gemaakt de koers niet nog een stuk hoger dan die 24 dollar gaat. Koers nu 19,50. Je kan dus op zeer korte termijn een hoop geld verdienen met Valeant. Gesprekken zijn in een vergevorderd stadium.

[verwijderd] 4 november 2016 16:08

Die stijging was om de vele die er nog iets uit wilde halen die kans te bieden beetje een hoax dus.

Valeant Pharmaceuticals International, Inc. (VRX)
Add to watchlist

NYSE - NYSE Real Time Price. Currency in USD

Quote Lookup

19,60+0,28 (+1,45%)
As of 11:05 AM EDT. Market open.

Wat ik denk is dat de bedrijfsvoerders het bedrijf deel voor deel verkopen dit omdat de toren hoge schulden en de div processen die er gaan lopen Valeant de kop gaan kosten.
Wat er nog weg kan worden gesluisd gebeurd.
Het is wat Fluctus zegt zeer glad ijs.

Ruud..

Diegy 4 november 2016 16:48

Ik ben in ieder geval zojuist ingestapt op 19,45. De verkoop zal misschien nabeurs of volgende week bekend worden gemaakt en reken maar dat dat nieuws de koers fors hoger zal zetten.

[verwijderd] 4 november 2016 16:52

quote:
Diegy schreef op 4 november 2016 16:48:
Ik ben in ieder geval zojuist ingestapt op 19,45. De verkoop zal misschien nabeurs of volgende week bekend worden gemaakt en reken maar dat dat nieuws de koers fors hoger zal zetten.

sterkte en succes ermee. :-)

353 Posts, Pagina: « 1 2 3 4 5 6 ... 10 11 12 13 14 15 16 17 18 » | Laatste

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	19 apr 2024 17:35
Koers	0,881
Verschil	+0,013 (+1,50%)
Hoog	0,889
Laag	0,869
Volume	8.926.686
Volume gemiddeld	6.927.541
Volume gisteren	37.599.271

Pharming nieuws meer

19 apr	Pharming lost voor 123 miljoen euro a...
18 apr	Pharming rondt plaatsing obligaties af	5
18 apr	Pharming vervangt converteerbare lening	6
08 apr	Pharming rondt rekrutering voor klini...
14 mrt	CEO: Pharming haalt omzet uit steeds ...	2
14 mrt	Lichte plus voor AEX voorzien; zullen...
14 mrt	Pharming rekent ook voor 2024 op dubb...	2
13 mrt	Slotcall: Twijfel slaat toe bij chipp...
11 mrt	Beursblik: hogere jaaromzet Pharming ...
11 mrt	AEX gaat opnieuw rode opening tegemoe...	1